Featured Stock: Juno Therapeutics Inc. (JUNO)
When we look at the Analyst Recommendations of the stock, the company has 1.92 rating given by Analysts where 1 stands for Strong Buy and 5 stands for Strong Sell.
A number of brokerages have commented on JUNO.
Juno Therapeutics Inc. on 9/29/2017 reported its EPS as $-0.65 with the analysts projecting the EPS of the stock as $-0.61. Citigroup restated a "buy" rating and set a $59.00 price objective on shares of Juno Therapeutics in a research report on Tuesday, October 31st. Wells Fargo & Co cut shares of Juno Therapeutics from an "outperform" rating to a "market perform" rating in a report on Tuesday, December 12th. Juno Therapeutics has a consensus rating of "Hold" and a consensus target price of $30.81. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and seven have given a buy rating to the company. 0 analysts gave its stock an Outperform rating.
Shares of Juno Therapeutics (NASDAQ JUNO) opened at $67.81 on Friday. Juno Therapeutics has a 1 year low of $19.07 and a 1 year high of $74.35. To measure price-variation, we found JUNO's volatility during a week at 6.2% and during a month it has been found around 4.89%. The volume of 8.43 Million shares climbed up over an trading activity of 2.64 Million shares.
Will Ferrell hilariously interviews Roger Federer at 2018 Australian Open
It's helped her start the new season feeling mentally fresh, as well. "I forgot to ask him if that was his real hair or a wig". The second round of the 2018 Australian Open continues on Wednesday (or Thursday for the players in Melbourne ).
Juno Therapeutics (NASDAQ:JUNO) last released its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.70) by $0.01. The firm had revenue of $44.80 million for the quarter, compared to the consensus estimate of $18.12 million.
Juno Therapeutics Inc. (NASDAQ:JUNO) gross margin percentage stands at 0% while its operating margin for the past trailing twelve month is 0 percent and its overall profit margin (ttm) is 0 Percent. The company reported revenue of $11.25 Million in the same period past year. On average, equities analysts forecast that Juno Therapeutics, Inc. will post ($2.98) earnings per share for the current year. Development, Harr Steve, sold 8,750 common shares of Juno Therapeutics, Inc. Through this figure traders can analyze that JUNO show whether or not a stock now most active and standing in buying side or sell side. Following the sale, the director now owns 824,985 shares of the company's stock, valued at $24,246,309.15. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The Weekly Volatility is 1.85% and the Monthly Volatility is 1.26%. The shares were sold at an average price of $44.76, for a total value of $391,650.00. Hedge funds and other institutional investors own 64.51% of the company's stock. Vanguard Group Inc. now owns 6,285,676 shares of the biopharmaceutical company's stock worth $187,879,000 after purchasing an additional 131,864 shares during the last quarter. Insiders own 15.08% of the company's stock.
Large investors have recently made changes to their positions in the stock. Following the completion of the transaction, the chief financial officer now owns 772,082 shares in the company, valued at approximately $34,558,390.32. Candriam Luxembourg S.C.A. bought a new position in shares of Juno Therapeutics in the third quarter worth $5,428,000. State Board of Administration of Florida Retirement System raised its position in shares of Juno Therapeutics by 11.9% in the fourth quarter. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.5283390096036 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term. Finally, Capital World Investors lifted its holdings in Juno Therapeutics by 13.8% in the 2nd quarter. Finally, Tudor Investment Corp Et Al acquired a new position in shares of Juno Therapeutics during the fourth quarter worth $215,000. Juno Therapeutics, Inc.is headquartered in Seattle, Washington. BlackRock Inc. lifted its holdings in Juno Therapeutics by 2.6% in the 2nd quarter.
Related:
-
Andy who? Briton Edmund reaches first grand slam quarter-final
Edmund found himself a set and a break behind but roared back to a historic victory. 'For me personally I'm happy to get through and keep doing my best'.Body of Montecito woman found, brings mudslide death toll to 21
There are now 16 human remain detection dog teams from throughout the state working together to locate missing victims. Tim Gubbins of the California Department of Transportation said Friday that U.S.Trump vs Kelly on the Border Wall
The Wall of 20,000 million dollars is "insignificance" compared to what Mexico earns with the United States. When Kelly was asked to describe Trump's proposed wall, he acknowledged, according to Democratic Rep. -
Marches supporting women, criticizing Trump held in Texas
The march, whose theme was " Power to the Polls ", was also meant to motivate people to the ballot box. She ran into a fraternity house where a party was going on, and students there called the police.Weekend Weather: Cloudy Saturday, Rain Sunday?
The high Monday could hit 39, and the next few days will be sunny with slowly rising temperatures, the weather service says. Along the line, damaging winds will be the primary concern, although a tornado or two can not be ruled out.Marin Cilic advances the quarterfinals of Australian Open
From that moment onwards, Carreno Busta lost nine consecutive points to meekly forfeit the third and couldn't wrest control back thereafter. -
Matches to Make After Bellator 192
The live event at the Forum has almost 20 fights on the schedule. "I want to knock somebody out or get knocked out doing it". It was an honor to compete with him. "I definitely feel like the best in the world after fighting with that guy".Anthony Martial helps Manchester United remain second
It is hard to be too critical of Burnley when considering that the Clarets have enjoyed a brilliant 2017-18 campaign to date . Both were disappointing on the afternoon, with the former replaced in the 72nd minute and the latter in the 80th.Referee should have watched video, says Chelsea boss Conte
This game had everything, including referee Graham Scott deciding not to use VAR on three penalty appeals for Chelsea . Chelsea had to play the final five minutes with just nine men as Championship side Norwich pressed for a victor . -
Government Shuts Down After Senate Rejects One-Month Stopgap Spending Bill
Although the House and Senate were in session Saturday, it was unclear whether lawmakers would take any votes of outcome . National parks and monuments could face closure, which provoked an angry public reaction during the 2013 shutdown .President Trump's Mar-a-Lago 1yr Celebration to go on Without Him
Lack of a funding bill agreement overnight pushed the USA into its first government shutdown since 2013. Democrats in the Senate say they will stand firm and filibuster another temporary funding bill.Trump's Doctor Attempts To Explain 'How Not Fat He Is' On SNL
Later in the show, SNL host Jessica Chastain delivered a monologue that was a musical tribute to the Women's March anniversary. The government may be shut down, but " Saturday Night Live " sketches about the president won't be any time soon.